An interventional study of Intensive Prevention Strategy in Type 2 Diabetes, Diabetic Cardiomyopathy and Heart Failure, sponsored by University of Texas Southwestern Medical Center. Recruiting at 3 sites in United States. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by University of Texas Southwestern Medical Center · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Diabetes Mellitus, Type 2 by University of Texas Southwestern Medical Center — 4 open to participants now, 5 under way, none of them phase 3. Diabetes Mellitus, Type 2 · University of Texas Southwestern Medical Center.
Among the 22 studies in Diabetes Mellitus, Type 2 by University of Texas Southwestern Medical Center, this one is the 4th largest by planned enrollment of the 19 interventional ones that give a count, is the only one that started in 2025, is one of 11 with no phase, and was the 22nd registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 22 studies in Diabetes Mellitus, Type 2 by University of Texas Southwestern Medical Center are open now, in 1 country. Recruiting first, the newest first:
University of Texas Southwestern Medical Center · Sites in United States
Ages 18–100
University of Texas Southwestern Medical Center · Sites in United States
Ages 18–60
University of Texas Southwestern Medical Center · Sites in United States
Ages 18–75
By country, each count listing its studies:
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 1993; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 120 across the 19 interventional studies, 22 across the 3 observational. Of the 16 that completed or were terminated, 9 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Texas Southwestern Medical Center is the lead sponsor of 1,012 studies on the registry; 200 are open to participants now.
Of its 139 completed or terminated interventional studies of FDA-regulated products, 105 (76%) have results posted.
3 of the studies in Diabetes Mellitus, Type 2 by University of Texas Southwestern Medical Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05168605University of Texas Southwestern Medical CenterAssessing the Efficacy of Targeted Home Visits in the Management of Chronic Conditions | 2026-12-31 |
| NCT06042153University of Texas Southwestern Medical CenterDIALYSIS-TIR Study | 2027-09 |
| NCT06143566University of Texas Southwestern Medical CenterPolypill for Prevention of Cardiomyopathy | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 22 studies in Diabetes Mellitus, Type 2 by University of Texas Southwestern Medical Center, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A pragmatic, randomized clinical trial to evaluate the effect of a heart failure (HF) risk assessment and prevention strategy incorporating HF clinical risk scores (WATCH-DM) with cardiac biomarker (NT-proBNP) paired with a clinical decision support tool to implement an intensive prevention strategy among patients with high risk focused on implementation of evidence-based HF preventive therapies.
Primary care providers will be randomized to receive notifications via the electronic health record if any patients with diabetes have high heart failure risk based on a combination of clinical risk scores(WATCH-DM), and biomarkers (NT-proBNP). Providers will be provided recommendation to initiate evidence based therapies (SGLT2 inhibitors, GLP1 agonists, non-steroidal MRA) , obtain expert e-consultation, or refer the patient to a cardiometabolic risk management program.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Primary care providers (PCP) randomized to the Risk Assessment and Intensive Prevention Strategy Arm will receive notification if any patients with diabetes under their care have high heart failure risk based on clinical or biomarker scores. Providers will receive recommendations, option for e-consultation, and referral to cardiometabolic risk management program.
Behavioral: Intensive Prevention Strategy
Primary care providers randomized to the Usual care arm will not receive any notifications about patients with diabetes and their HF risk assessment.
Providers randomized to the intensive prevention strategy will receive notification about patients with diabetes who have high heart failure risk and recommendations for medical management, e-consultation, or referral to a cardiometabolic risk management program.
Incident Heart Failure or All-cause death
Incident Heart Failure (based on electronic health record International Classification of Diseases codes) or all-cause death. This will be assessed via retrospective chart review.
Time frame: 2-year follow-up
Prescription Rates of SGLT2i
Counts of SGLT2 inhibitor prescriptions filled
Time frame: 6-months from electronic health record alert.
Prescription Rate of Finerenone
Counts of Finerenone prescriptions
Time frame: 6-months from electronic health record alert.
Prescription Rate of GLP1
Counts of GLP1 prescription
Time frame: 6-months from electronic health record alert.
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2025 (actual). Primary completion is estimated for Dec 2027, 34 months after the start.
Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 34 months is above that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Texas Southwestern Medical Center →